Development and characterization of Luliconazole Loaded Solid Lipid Nanoparticles for Topical Delivery
DOI:
https://doi.org/10.22270/ajprd.v12i6.1458Abstract
Superficial fungal infections in immunocompromised patients can lead to various disorders and complications. There is a critical need for new topical treatment options for these fungal infections. Luliconazole (LUZ) is a topical antifungal medicine used to treat fungal infections. This paper aims to develop a new topical gel incorporating Luliconazole SLN (LUZ-SLN). The study suggests that LUZ-SLN embedded in a gel could serve as an effective drug delivery system for topical antifungal treatments. Initial experiments were conducted to characterize the LUZ-SLN and compare it with the raw drug. The prepared gel was found to be homogeneous, safe for human use, and non-irritating. The nano-systems demonstrated a 5-fold enhancement in solubility, a s4-fold increase in dissolution velocity, greater skin retention, and improved antifungal activity. The LUZ-SLN gel showed the highest drug retention in different skin layers within 8 hours. Additionally, both LUZ-SLN and Control exhibited higher ZOI (Zone of Inhibition) values (93mm and 87mm, respectively) compared to marketed cream (83mm ). This suggests that the LUZ-SLN-loaded gel was more effective in combating the fungus. Therefore, the LUZ-SLN-loaded gel presents a new approach with improved activity and enhanced dermal delivery for drugs with poor aqueous solubility, compared to traditional drug-containing gel formulations.
Downloads
References
Kumar M, Kumar P, Singh N, Paul P, Singh L, Kumar S, Kumar A. Designing of luliconazole (lcz) in aloe vera gel loaded solid lipid nanoparticle and its evaluation. International Journal of Pharmaceutical Research (09752366). 2021 Apr 1;13(2).
Speiser P. Lipidnanopellets als Trägersystem für Arzneimittel zur peroralen Anwendung. European Patent EP. 1990 Aug 8; 167825:0167825.
Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Advanced drug delivery reviews. 2007 Jul 30; 59(7):677-94.
Chen HY, Fang JY. Therapeutic patents for topical and transdermal drug delivery systems. Expert Opinion on Therapeutic Patents. 2000 Jul 1; 10(7):1035-43.
Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. International journal of pharmaceutics. 1999 Jul 5; 184(1):1-6.
Kreilgaard M. Influence of microemulsions on cutaneous drug delivery. Advanced drug delivery reviews. 2002 Nov 1; 54:S77-98.
Singh SK, Durrani MJ, Reddy IK, Khan MA. Effect of permeation enhancers on the release of ketoprofen through transdermal drug delivery systems. Die Pharmazie. 1996 Oct 1; 51(10):741-4.
Panchagnula R. Transdermal delivery of drugs. Indian journal of pharmacology. 1997 May 1; 29(3):140-56.
Sinha VR, Kaur MP. Permeation enhancers for transdermal drug delivery. Drug development and industrial pharmacy. 2000 Jan 1; 26(11):1131-40.
Nirmal K, Karki AA, Rita C, Manoj C, Bhushan G. An overview of antifungal therapy. Int. J. Biomed. Adv. Res. 2011; 2:69-85.
Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Advanced drug delivery reviews. 2007 Jul 10;59(6):522-30.
Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood–brain barrier penetration. International journal of pharmaceutics. 2011 Sep 15; 416(1):331-8.
Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco MR. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. International journal of pharmaceutics. 2000 Dec 4; 210(1-2):61-7.
Muller RH, Runge SA. Solid lipid nanoparticles (SLN) for controlled drug delivery. Submicron emulsions in drug targeting and delivery. 1998 Dec 16; 219:234.
RH M. Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Biopharm. 1995;41:62-9.
Müller RH, Radtke M, Wissing S. Nanostructured lipid matrices for improved microencapsulation of drugs. International journal of pharmaceutics. 2002 Aug 21; 242(1-2):121-8.
Olbrich C, Gessner A, Schröder W, Kayser O, Müller RH. Lipid–drug conjugate nanoparticles of the hydrophilic drug diminazene—cytotoxicity testing and mouse serum adsorption. Journal of Controlled Release. 2004 May 18; 96(3):425-35.
Wong HL, Rauth AM, Bendayan R, Wu XY. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. European journal of pharmaceutics and biopharmaceutics. 2007 Mar 1; 65(3):300-8.
Bellavance MA, Poirier MB, Fortin D. Uptake and intracellular release kinetics of liposome formulations in glioma cells. International journal of pharmaceutics. 2010 Aug 16;395(1-2):251-9.
Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Advanced drug delivery reviews. 2007 Jul 10; 59(6):522-30.
Tsai YM, Chien CF, Lin LC, Tsai TH. Curcumin and its nano-formulation: the kinetics of tissue distribution and blood–brain barrier penetration. International journal of pharmaceutics. 2011 Sep 15; 416(1):331-8.
Muller RH, Runge SA. Solid lipid nanoparticles (SLN) for controlled drug delivery. Submicron emulsions in drug targeting and delivery. 1998 Dec 16; 219:234.
Jenning V, Thünemann AF, Gohla SH. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. International journal of pharmaceutics. 2000 Apr 20; 199(2):167-77.
Lim SJ, Kim CK. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. International journal of pharmaceutics. 2002 Aug 28; 243(1-2):135-46.
Jee JP, Lim SJ, Park JS, Kim CK. Stabilization of all-trans retinol by loading lipophilic antioxidants in solid lipid nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics. 2006 Jun 1; 63(2):134-9.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Muktai N. Rudrurkar, Vishweshwar M. Dharashive, Dr. Sameer Shafi, Anis J. Kazi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.